- Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. Antiviral Therapy. 2017 Academic Article GET IT
Two-year safety and virologic efficacy of maraviroc in treatment- experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Journal of Acquired Immune Deficiency Syndromes.
Times cited: 62